secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-125195
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics appoints Ronald A. Andrews to board; Robert Lenk resigns
--------------------------------------------------------------------------

- Robert Lenk resigned as director and Nominating Committee member effective March 20, 2026; no policy disagreement cited.
- Ronald A. Andrews appointed to fill vacancy, effective immediately; will stand for reelection at 2026 annual meeting.
- Andrews is independent under Nasdaq rules; appointed to Nominating and Corporate Governance Committee.
- Andrews brings 35+ years in diagnostics; currently Founder/Managing Partner of The Bethesda Group.
- No transactions requiring SEC disclosure; standard indemnification agreement expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526125195/0001193125-26-125195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526125195/pstv-20260320.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-125195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer